Despite 50 years of research, there are currently no RSV vaccines approved or in Phase III trials for any of the target populations. High levels of neutralizing antibodies to RSV F protein have ...

Nasal vaccine devices have the potential to offer more convenient and more effective protection against a variety of viruses.

[and] we’ve got a monoclonal antibody we can give to a baby that’s vulnerable, so we can decrease infections [in] kids.” Dr Raman said with increased education around RSV and vaccination ...

This is because how can the world's third largest Pharma by revenues in 2023 — $58.5bn — be worth nearly five times less than e.g., Eli Lilly ... a vaccine against RSV, which will generate ...

Exceptions are respiratory syncytial virus monoclonal antibody (RSVAb) and transfusion of washed red ... Because pharmacokinetic properties of Ig G following SCIg administration have been shown to ...

There are currently around 200 SARS-CoV-2 candidate vaccines in preclinical and clinical trials throughout the world. The various candidates employ a range of vaccine strategies including some novel ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.